Search research articles
Contact Us
Filters
Showing results (291-300 of 326) with videos related to
Page
of 33
Sort By:
BMC Pediatrics
|
October 24, 2019
Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis
Chee Y Ooi, Rosie Sutherland, Carlo Castellani, et al.
Annals of the American Thoracic Society
|
January 19, 2021
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
Nicole Mayer-Hamblett, David P Nichols, Katherine Odem-Davis, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 2, 2018
Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement
Paul D Robinson, Philipp Latzin, Kathryn A Ramsey, et al.
The Journal of Pediatrics
|
March 11, 2017
Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis
Robin Z Hayeems, Fiona A Miller, Carolyn J Barg, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 15, 2023
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Jennifer L Goralski, Jordana E Hoppe, Marcus A Mall, et al.
Pediatrics
|
May 13, 2015
Inconclusive diagnosis of cystic fibrosis after newborn screening
Chee Y Ooi, Carlo Castellani, Katherine Keenan, et al.
Pediatrics
|
August 4, 2016
Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis
Robin Z Hayeems, Fiona A Miller, Carolyn J Barg, et al.
The European Respiratory Journal
|
May 2, 2024
A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment
Valerie Waters, Michelle Shaw, Lucy Perrem, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension Study
Claire Wainwright, Susanna A McColley, Paul McNally, et al.
NPJ Genomic Medicine
|
June 27, 2017
Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
Saumel Ahmadi, Zoltan Bozoky, Michelle Di Paola, et al.
Page
of 33
Search research articles
Search
Showing results (291-300 of 326) with videos related to
Sort By:
Page
of 33
BMC Pediatrics
|
October 24, 2019
Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis
Chee Y Ooi, Rosie Sutherland, Carlo Castellani, et al.
Annals of the American Thoracic Society
|
January 19, 2021
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
Nicole Mayer-Hamblett, David P Nichols, Katherine Odem-Davis, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 2, 2018
Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement
Paul D Robinson, Philipp Latzin, Kathryn A Ramsey, et al.
The Journal of Pediatrics
|
March 11, 2017
Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis
Robin Z Hayeems, Fiona A Miller, Carolyn J Barg, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 15, 2023
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Jennifer L Goralski, Jordana E Hoppe, Marcus A Mall, et al.
Pediatrics
|
May 13, 2015
Inconclusive diagnosis of cystic fibrosis after newborn screening
Chee Y Ooi, Carlo Castellani, Katherine Keenan, et al.
Pediatrics
|
August 4, 2016
Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis
Robin Z Hayeems, Fiona A Miller, Carolyn J Barg, et al.
The European Respiratory Journal
|
May 2, 2024
A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment
Valerie Waters, Michelle Shaw, Lucy Perrem, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 2, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A 192-Week, Phase 3, Open-Label Extension Study
Claire Wainwright, Susanna A McColley, Paul McNally, et al.
NPJ Genomic Medicine
|
June 27, 2017
Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
Saumel Ahmadi, Zoltan Bozoky, Michelle Di Paola, et al.
Page
of 33